CRL Similar Chart Price Prediction
The price of CRL is predicted to go up 2.19%, based on the high correlation periods with AMD. The similarity of these two price pattern on the periods is 98.26%.
CRL
AMD
Up: 2.19%Similarity: 98.26%
CRL Revenue Forecast
CRL EPS Forecast
CRL FAQs
What is bull’s view on CRL?
What is bear's view on CRL?
What is CRL revenue forecast for next quarter？
What is CRL eps forecast for next quarter？
CRL VS S&P500
Charles River's reputation for quality and scientific expertise supports its leading position in the research model and preclinical trial markets.
The company's contract research business should benefit from robust biotech demand and funding.
The high-margin manufacturing support segment should boost earnings for the company as it grows.
CRL Analyst's Forecast
Dan Leonard
UBS
Strong Buy → Hold
Price Target
$250 → $185
Upside
+13.15%
UBS downgraded Charles River to Neutral from Buy with a price target of $185, down from $250. The Neutral rating reflects a view that the company's mid-term sales growth has "structurally decelerated," the analyst tells investors in a research note. The firm says this view is supported not only by Charles River's recent results and outlook, but peer read-across, pricing trends, and updated market analysis. UBS remains constructive on Charles River's positioning as a key enabler to biopharma, and its opportunity to execute on cost reductions, however.
Derik De Bruin
B of A Securities
Hold
Price Target
$220 → $210
Upside
+10.26%
Charles Rhyee
TD Cowen
Hold
Price Target
$203 → $227
Upside
+2.81%